CG MED EQUIP.
838810
BEOKA
870199
Shenzhen Bromake New Material
301387
4
Zhejiang Hongchang Electrical Technology
301008
5
Wuhan Lincontrol Automotive Electronics Co., Ltd.
688667
CN Stock MarketDetailed Quotes
300436 Fujian Cosunter Pharmaceutical
- 30.05
- +0.66+2.25%
Market Closed Apr 30 15:00 CST
4.79BMarket Cap-28.14P/E (TTM)
30.20High29.39Low19.97KlotVolume29.39Open29.39Pre Close59.84MTurnover1.46%Turnover RatioLossP/E (Static)159.27MShares41.2052wk High14.43P/B4.11BFloat Cap14.1652wk Low35.27Limit Up136.72MShs Float166.92Historical High23.51Limit Down2.76%Amplitude12.28Historical Low--Dividend TTM29.96Avg Price8.85KlotAsk--Div YieldTTM100Lot Size10.69KlotBid
Fujian Cosunter Pharmaceutical Key Stats
All
YOY
| (Q3)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ||||||||||
| Goods sale service render cash | -14.37%111.55M | 7.35%487.91M | 14.87%371.16M | 20.35%247.1M | 30.42%130.27M | 3.03%454.5M | -2.29%323.11M | -5.73%205.32M | -9.82%99.89M | 7.21%441.13M |
| Refunds of taxes and levies | ---- | ---- | ---- | ---- | ---- | -69.56%1.86M | --1.86M | ---- | ---- | --6.1M |
| Cash received relating to other operating activities | 52.24%5M | 406.55%84.7M | 85.64%18.18M | 59.12%14.53M | -27.64%3.28M | -15.83%16.72M | -37.53%9.79M | 9.37%9.13M | 32.69%4.54M | -28.48%19.87M |
| Cash inflows from operating activities | -12.74%116.54M | 21.04%572.61M | 16.30%389.35M | 22.00%261.64M | 27.89%133.55M | 1.28%473.08M | -3.35%334.76M | -5.17%214.46M | -8.54%104.43M | 6.34%467.1M |
| Goods services cash paid | -63.53%14.61M | -14.19%147.49M | -34.04%94.12M | -29.71%78.43M | -45.98%40.05M | 29.99%171.88M | 23.49%142.7M | 109.44%111.58M | 273.86%74.14M | 25.47%132.22M |
| Staff behalf paid | -7.19%43.23M | 5.82%150.32M | -1.23%113.46M | -2.03%80.37M | 2.35%46.58M | 11.35%142.05M | 21.12%114.87M | 25.23%82.03M | 27.98%45.51M | 17.60%127.57M |
| All taxes paid | 30.56%14.63M | 6.30%59.61M | -8.23%42.19M | -16.64%27.77M | -43.65%11.21M | 2.95%56.08M | 65.93%45.97M | 119.40%33.31M | 92.61%19.89M | 71.10%54.47M |
| Cash paid relating to other operating activities | 15.71%56.63M | -29.96%194.49M | -19.16%157.01M | -31.27%97.54M | -41.32%48.94M | 1.89%277.68M | 4.43%194.23M | 10.03%141.92M | 23.02%83.4M | 28.97%272.52M |
| Cash outflows from operating activities | -12.04%129.1M | -14.79%551.9M | -18.28%406.78M | -22.97%284.1M | -34.16%146.77M | 10.38%647.68M | 17.37%497.77M | 40.28%368.84M | 66.98%222.94M | 28.40%586.78M |
| Net cash flows from operating activities | 5.05%-12.55M | 111.86%20.71M | 89.30%-17.44M | 85.45%-22.47M | 88.84%-13.22M | -45.89%-174.6M | -109.72%-163.01M | -319.69%-154.38M | -513.17%-118.51M | -573.69%-119.68M |
| Investing cash flow | ||||||||||
| Cash received from returns on investments | ---- | 19,575.90%17.68M | --17.64M | --17.64M | --17.64M | -69.93%89.85K | ---- | ---- | ---- | --298.83K |
| Net cash received from disposal of fix assets、 intangible assets 、other long-term asset | --5.6K | 13,480.16%4.5M | -99.55%150 | -99.39%150 | ---- | 34.44%33.16K | 1,479.88%33.16K | --24.5K | --24.5K | 10.97%24.67K |
| Cash received relating to other investing activities | ---- | -76.30%10.25M | ---- | ---- | ---- | 1,341.67%43.25M | ---- | ---- | ---- | --3M |
| Cash inflows from investing activities | -99.97%5.6K | -25.22%32.43M | 53,094.27%17.64M | 71,900.61%17.64M | 71,900.00%17.64M | 1,205.04%43.37M | 1,479.88%33.16K | --24.5K | --24.5K | 14,851.12%3.32M |
| Cash paid to acquire fixed assets intangible assets and other long-term assets | -53.83%11.49M | -66.71%66.99M | -77.36%46.83M | -78.02%34.87M | -72.98%24.89M | 2.69%201.24M | 31.74%206.86M | 11.93%158.65M | 44.90%92.12M | 12.36%195.96M |
| Cash paid to acquire investments | ---- | -88.92%1.06M | -87.06%1.06M | --1.06M | --1.06M | 508.59%9.54M | --8.17M | ---- | ---- | --1.57M |
| Cash paid relating to other investing activities | ---- | -74.50%10.2M | ---- | ---- | ---- | 1,233.33%40M | ---- | ---- | ---- | --3M |
| Cash outflows from investing activities | -55.72%11.49M | -68.80%78.24M | -77.73%47.89M | -77.35%35.93M | -71.84%25.94M | 25.06%250.78M | 36.94%215.03M | 11.93%158.65M | 44.90%92.12M | 14.98%200.53M |
| Net cash flows from investing activities | -38.28%-11.48M | 77.91%-45.81M | 85.93%-30.25M | 88.47%-18.29M | 90.98%-8.3M | -5.17%-207.41M | -36.92%-214.99M | -11.91%-158.63M | -44.86%-92.1M | -13.09%-197.21M |
| Financing cash flow | ||||||||||
| Cash received from capital contributions | ---- | ---- | ---- | ---- | ---- | 337.36%220M | ---- | ---- | ---- | -90.02%50.3M |
| -Including: Cash received from capital contributions by minority shareholders of subsidiaries | ---- | ---- | ---- | ---- | ---- | 528.57%220M | ---- | ---- | ---- | --35M |
| Cash from borrowing | -45.92%53M | -12.75%350.8M | -29.32%239M | -33.94%185.13M | -21.07%98M | 8.02%402.06M | 53.71%338.16M | 143.68%280.23M | 67.80%124.16M | 144.33%372.2M |
| Cash received relating to other financing activities | ---- | ---- | ---- | ---- | ---- | 2,663.64%31.92M | 1,337.33%220M | 1,337.33%220M | --220M | --1.16M |
| Cash inflows from financing activities | -45.92%53M | -46.36%350.8M | -57.18%239M | -62.99%185.13M | -71.53%98M | 54.37%653.98M | 106.49%558.16M | 204.25%500.23M | 247.30%344.16M | -35.44%423.65M |
| Borrowing repayment | -30.49%49.45M | 44.28%367.23M | 31.87%253.73M | 61.85%207.27M | 81.49%71.15M | 2.49%254.53M | 62.85%192.41M | 79.60%128.06M | -12.40%39.2M | 28.82%248.35M |
| Dividend interest payment | -14.63%3.96M | -4.67%17.42M | 2.71%13.22M | 19.48%9.08M | 41.38%4.64M | 58.62%18.27M | 51.63%12.87M | 30.92%7.6M | 56.17%3.28M | 25.62%11.52M |
| -Including:Cash payments for dividends or profit to minority shareholders | ---- | ---- | ---- | ---- | ---- | -25.00%874.5K | ---- | ---- | ---- | --1.17M |
| Cash payments relating to other financing activities | ---- | -98.06%611.28K | -93.33%90K | ---- | ---- | 2,419.85%31.46M | 1,032.87%1.35M | --750K | --500K | -85.61%1.25M |
| Cash outflows from financing activities | -29.52%53.41M | 26.62%385.26M | 29.23%267.04M | 58.60%216.35M | 76.32%75.78M | 16.52%304.27M | 63.01%206.63M | 76.90%136.41M | -8.26%42.98M | 23.96%261.12M |
| Net cash flows from financing activities | -101.85%-410.42K | -109.85%-34.46M | -107.98%-28.04M | -108.58%-31.22M | -92.62%22.22M | 115.16%349.71M | 144.89%351.52M | 316.73%363.82M | 476.47%301.18M | -63.52%162.53M |
| Net cash flow | ||||||||||
| Exchange rate change effecting cash and cash equivalents | ---- | -89.55%330.13 | ---- | ---- | ---- | 127.47%3.16K | ---- | ---- | ---- | ---11.5K |
| Net increase in cash and cash equivalents | -3,642.49%-24.45M | -84.48%-59.56M | -185.97%-75.72M | -241.67%-71.98M | -99.24%690.12K | 79.08%-32.29M | 70.97%-26.48M | 155.69%50.81M | 395.42%90.57M | -160.91%-154.36M |
| Add:Begin period cash and cash equivalents | -29.41%142.96M | -13.75%202.52M | -13.75%202.52M | -13.75%202.52M | -13.75%202.52M | -39.66%234.81M | -39.66%234.81M | -39.66%234.81M | -39.66%234.81M | 186.70%389.17M |
| End period cash equivalent | -41.68%118.51M | -29.41%142.96M | -39.14%126.8M | -54.29%130.54M | -37.55%203.21M | -13.75%202.52M | -30.08%208.33M | -4.14%285.61M | -9.24%325.38M | -39.66%234.81M |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion |
| Auditor | -- | Beijing Dehao International Accounting Firm (Special General Partnership) | -- | -- | -- | Dahua Certified Public Accountants (Special General Partnership) | -- | -- | -- | Dahua Certified Public Accountants (Special General Partnership) |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.